Compared to normal tissues, BST‐2 expression in lung adenocarcinoma and thyroid cancer is unchanged 119 whereas levels of BST‐2 in lung squamous cell carcinoma, kidney papillary cell carcinoma, kidney chromophobe carcinoma, liver, and prostate cancer is significantly downregulated 119. Here, BST2 is linked to chromophobe renal cell carcinoma.